false
0001014763
0001014763
2026-11-12
2026-11-12
0001014763
AIMD:CommonStockParValue0.01PerShareMember
2026-11-12
2026-11-12
0001014763
AIMD:WarrantsToPurchaseCommonStockMember
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 12, 2026
AINOS,
INC.
(Exact
name of registrant as specified in its charter)
| Texas |
|
001-41461 |
|
75-1974352 |
(State
or other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
3050
Post Oak Blvd, Suite 510-T80, Houston, TX 77056
(281)
898-6586
(Address
and telephone number, including area code, of registrant’s principal executive offices)
(Former
name or former address if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.01 per share |
|
AIMD |
|
The
Nasdaq Stock Market LLC |
| Warrants
to purchase Common Stock |
|
AIMDW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement
On
November 12, 2026, Ainos, Inc. (the “Company”), entered into an AI NOSE Equipment Sale and Purchase Agreement (the “Agreement”)
with ASE Technology Holding Co., Ltd. (“ASE”). Under the Agreement, the Company agreed to sell, and ASE agreed to purchase,
a total of 5,000 units of the Company’s AI NOSE equipment (the “Equipment”). The delivery schedule, batches and locations
will be confirmed in writing by the parties in accordance with ASE’s deployment plan.
Pursuant
to the Agreement, the total purchase price of the Equipment is US$9,000,000. ASE is required to pay a deposit equal to 50% of the total
purchase price, or US$4,500,000, within 60 days after the date the Agreement is signed. The remaining 50% is payable after the Company
completes delivery of all of the Equipment and submits delivery and billing documents to ASE.
In
addition, pursuant to the Agreement, beginning on the day after the first anniversary of the delivery acceptance date of each unit, and
for so long as ASE owns and uses the Equipment, ASE will pay the Company ongoing annual maintenance fee, covering platform usage, technical
updates and AI algorithm upgrade services.
The
foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text
of the Agreement, an English translation of which is filed with this current report on Form 8-K as Exhibit 10.1 and is hereby incorporated
herein by reference.
Item
7.01 Regulation FD Disclosure
On
November 12, 2026, the Company announced the execution of the Agreement with ASE. A copy of the press release issued by the Company in
this connection is furnished herewith as Exhibit 99.1.
The
information furnished with this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended,
or the Exchange Act.
Item
9.01 Financial Statement and Exhibits
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 10.1* |
|
English Translation of AI Nose Equipment Sale and Purchase Agreement, dated November 12, 2026 |
| 99.1 |
|
Press Release dated November 12, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
*
Certain portions of this Exhibit were redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company hereby agrees to furnish
a copy of any omitted portion to the Securities and Exchange Commission upon request.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Ainos,
Inc. |
| |
|
| Date:
November 17, 2026 |
By: |
/s/
Chun-Hsien Tsai |
| |
Name: |
Chun-Hsien
Tsai |
| |
Title: |
Chief
Executive Officer |
Exhibit
99.1
Ainos
Secures Largest Order in Company History: $9 Million ASE Agreement for 5,000 Additional AI Nose Systems
Follow-on
order marks progression from field validation and first-phase delivery to scaled commercial adoption of Chemical Intelligence in advanced
packaging $4.5 million deposit payable within 60 days of signing will support order fulfillment and working capital
Ainos,
Inc. (NASDAQ:AIMD, AIMDW) (“Ainos” or the “Company”) today announced that it has signed a $9 million purchase
agreement with ASE Technology Holding Co., Ltd. (“ASE”) for 5,000 additional AI Nose systems. The agreement represents the
largest single purchase order by value in Ainos’ history and marks a new phase of commercial scale for its Chemical Intelligence
platform in advanced semiconductor manufacturing.
The
purchase builds on the completed delivery of 1,400 systems under the companies’ previous $2.1 million agreement. At approximately
4.3 times the value of the prior $2.1 million agreement, ASE’s expanded commitment follows experience with the initial deployment
and deepens the companies’ commercial relationship. It also provides tangible evidence of Ainos’ progression from concept
development and field validation to initial delivery and scaled commercial adoption.
Under
the agreement, ASE will pay a 50% deposit of $4.5 million within 60 days of signing. The remaining 50% is payable with a payment request
submitted after delivery and supported by delivery documentation. This structure will support order fulfillment and working capital needs,
while the agreement establishes a larger revenue base for the Company. Revenue will be recognized in accordance with applicable accounting
standards as contractual performance obligations are satisfied.
“From
field validation and first-phase delivery to ASE’s expanded purchase, this record order demonstrates how Chemical Intelligence
is progressing from technology development to a business operating at greater scale,” said Eddy Tsai, Chairman and Chief Executive
Officer of Ainos. “Our customer’s larger commitment deepens the relationship and provides a revenue foundation and funding
to support our next stage of growth. We are focused on delivering these systems and continuously improving our products so that chemical
information can create greater value in process stability, yield improvement and worker safety.”
“As
advanced packaging technologies evolve, ASE continues to advance smart manufacturing through new sensing capabilities,” said a
senior executive of ASE. “Together with Ainos, we are expanding chemical sensing coverage to develop a more comprehensive view
of conditions across our manufacturing operations. Our joint effort aims to integrate chemical insights with existing manufacturing data
to support better-informed decisions on yield and quality, operational efficiency, and personnel safety.”
Supporting
Yield, Efficiency and Safety in Advanced Packaging
Advanced
packaging places stringent demands on process consistency, contamination control and product reliability. As a physical edge node for
Chemical Intelligence, AI Nose converts airborne chemical signals into digital information that can be analyzed. It helps engineering
teams establish environmental baselines, compare chemical conditions across locations, and track where anomalies emerge and how they
evolve—complementing existing process and equipment data.
The
expanded deployment will broaden chemical sensing coverage across relevant ASE manufacturing environments, supporting three target objectives:
| ● | Yield
and quality: Support contamination management and anomaly investigation, helping teams
maintain stable process environments and informing efforts to improve yield and product reliability. |
| ● | Efficiency
and profitability: Identify environmental changes that may contribute to defects, rework
or unplanned downtime, supporting efforts to reduce production losses and improve operational
efficiency. |
| ● | Worker
and facility safety: Support the identification of, and response to, chemical leaks or
abnormal releases, helping teams reduce the risk of personnel exposure, equipment damage
and operational disruption. |
Real-World
Data Supports Continuous Improvement and Semiconductor Expansion
Ainos’
AI Nose platform has accumulated more than 3 billion real-world chemical data points. These data and field experience provide a foundation
for ongoing improvements in system stability, chemical signal analysis and application development. Broader deployment also advances
the Company’s Chemical Intelligence and Scent AI strategy: physical sensing nodes collect real-world data to support model learning
and product improvement, with customer value providing the foundation for wider adoption. Data use will remain subject to customer permissions
and protection requirements, and product performance will be validated under application-specific conditions.
In
front-end wafer fabrication, Ainos announced in September 2026 that it had begun receiving initial commercial orders following technical
validation. The expansion in advanced packaging, together with commercial progress in front-end manufacturing, broadens the Company’s
semiconductor business foundation. It also provides experience that can support engagement with additional international customers and
the development of monitoring applications in other industrial and healthcare environments, with new applications subject to validation
against their specific requirements.
About
AI Nose
AI
Nose digitizes scent and chemical signals into machine-readable Smell ID data. Combining proprietary sensing hardware, edge AI, cloud-based
fleet management, and a growing library of real-world chemical data, AI Nose enables machines to detect, distinguish, and learn from
environmental signals that conventional vision and audio systems cannot capture. Ainos is developing AI Nose as a foundation for Chemical
Intelligence across semiconductor manufacturing, robotics, industrial monitoring, healthcare, and other Physical AI applications.
About
Ainos, Inc.
Ainos,
Inc. (NASDAQ:AIMD) is building Chemical Intelligence for Physical AI, giving machines a new way to understand the physical world by turning
chemical signals in the air into digital information. Its AI Nose technology enables intelligent systems to sense and interpret changes
in their surroundings, while Atmosphere Engine extends that intelligence toward environmental control. Together, they form a sensing-to-control
architecture designed to help machines sense, understand, and ultimately optimize their environments across semiconductor manufacturing,
robotics, industrial systems, healthcare environments, and other real-world applications where AI increasingly interacts with the physical
world. Follow Ainos on X, formerly known as Twitter, @AinosInc, and LinkedIn to stay up to date. Visit Ainos’ media
room at https://ainos.suite.accessnewswire.com.
Forward-Looking
Statements
Certain
statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking
statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends,
which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other
events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of
important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated
by the forward-looking statements in this press release. These factors include, among other things, the uncertainty of the contemplated
collaboration framework and the expected receipt of license fees, manufacturing license fees and other consideration thereunder; our
expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional
capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our
current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates
we develop; the ability to obtain and maintain regulatory approval of our licensed indications and product candidates; delays in completing
the development and commercialization of our current and future product candidates; developing and commercializing additional products,
including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs,
and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking
statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required
by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information,
future events and developments or otherwise.
Investor
Relations
ir@ainos.com